Trademark Overview
On Wednesday, May 20, 2026, a trademark application was filed for DISRUPTIDE with the United States Patent and Trademark Office. The USPTO has given the DISRUPTIDE trademark a serial number of 99834893. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, May 20, 2026. This trademark is owned by Rime Therapeutics Inc.. The DISRUPTIDE trademark is filed in the Chemical Products and Computer & Software Services & Scientific Services categories with the following description:
chemical preparations and reagents, namely, peptide sequences and peptide probes for use in drug discovery and development; AI-designed peptide probes for use in drug discovery and development; live-cell functional assays and drug screen assays involving engineered peptide probes, for research purposes; engineered peptide probes for live-cell phenotypic screening, intracellular target identification and validation, generation of molecular chemical profiles of function hits at defined target sites, and peptide-based drug discovery and development; genetically-deliverable peptide sequences and peptide probes for preserving peptide conformation, minimizing steric interference, and enhancing peptide intracellular stability
Drug and drug target discovery services; Design, development, and engineering of peptide sequences and peptide probes for use in drug discovery and development; Medical scientific research, analysis, and testing, namely, using engineered peptide probes in live-cell phenotypic screening, intracellular target identification and validation, generation of molecular chemical profiles of function hits at defined target sites, and peptide-based drug discovery and development; Using AI-designed peptide probes to conduct research, testing, and analysis of peptide-target pairs as molecular blueprints for developing small molecule inhibitors; Providing medical scientific information, advisory, and consultancy services in the fields of peptides, peptide-based drug discovery and development, and phenotypic drug screening
